Mettler-Toledo InternationalFRA:MTO +4.04%90 EBITDA Margin % is 27.39% as of Mar. 2026, which is 6% below its 10-year median of 29.16. GuruFocus rates FRA:MTO with a GF Score™ of 90/100 and a GF Value™ of €1,206.32 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 204 Medical Diagnostics & Research companies, Mettler-Toledo International ranks better than 90.2% on this metric.
Mettler-Toledo International (FRA:MTO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Mettler-Toledo International EBITDA Margin % Related Terms
Mettler-Toledo International EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mettler-Toledo International EBITDA Margin % Chart
FRA:MTO vs ILMN, DGX, LH: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Mettler-Toledo International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mettler-Toledo International EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Mettler-Toledo International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Mettler-Toledo International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mettler-Toledo International (FRA:MTO) has a EBITDA Margin % of 27.39% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mettler-Toledo International and its competitors. This is near median its historical median of 29.16. Over the past decade, Mettler-Toledo International's EBITDA Margin % has ranged from 23.96 to 31.89. According to the industry distribution chart, Mettler-Toledo International ranks #20 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 9.8%.
Is Mettler-Toledo International's EBITDA Margin % too high?
Mettler-Toledo International's current EBITDA Margin % of 27.39% is near median its 10-year median of 29.16. Over the past 10 years, this metric has ranged from a low of 23.96 to a high of 31.89. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Mettler-Toledo International's value of 27.39% is 426.7% above this industry median. Based on the distribution chart, Mettler-Toledo International ranks #20 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Mettler-Toledo International has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mettler-Toledo International's EBITDA Margin % compare to ILMN and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Mettler-Toledo International ranks #20 out of 204 companies for EBITDA Margin %. This places Mettler-Toledo International in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Mettler-Toledo International's value of 27.39% is 426.7% above this benchmark. Historically, Mettler-Toledo International's own EBITDA Margin % has ranged from 23.96 to 31.89 over the past decade. While the company's 10-year median is 29.16 vs. the industry median of 5.20, Mettler-Toledo International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mettler-Toledo International's current EBITDA Margin % of 27.39% is 426.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mettler-Toledo International and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mettler-Toledo International's current EBITDA Margin % is 27.39%, which is near median its own 10-year median of 29.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mettler-Toledo International stock overvalued right now?
Based on GuruFocus' analysis, Mettler-Toledo International (FRA:MTO) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,206.32, compared to a current price of €1,055.00 — trading 12.5% below its estimated fair value. The current EBITDA Margin % is 27.39%, which is near median its 10-year median of 29.16 and 426.7% above the Medical Diagnostics & Research industry median of 5.20. Mettler-Toledo International's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Mettler-Toledo International (FRA:MTO), the current EBITDA Margin % is 27.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mettler-Toledo International (FRA:MTO) Overvalued in 2026?
Based on GuruFocus' analysis, Mettler-Toledo International stock appears to be undervalued.
The current stock price of €1,055.00 is trading 12.5% below its estimated GF Value™ of €1,206.32.
GuruFocus considers Mettler-Toledo International to be Modestly Undervalued.
Key valuation signals for FRA:MTO:
EBITDA Margin %: 27.39% (near median its 10-year median of 29.16)
GF Value™: €1,206.32 vs. price of €1,055.00 (12.5% below fair value)
Industry Position: 426.7% above the Medical Diagnostics & Research median (#20 of 204)
No single metric tells the full story. See the FRA:MTO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 27%, China about 16% and the rest of the world about 20%.
90GF Score
Get the complete analysis for FRA:MTO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MTO has been successfully added to your 
